---

---

treatment   publishing date : 2021 - 09 - 07   

save search

---

ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Published: 2021-09-07 (Crawled : 20:00) - globenewswire.com
MS | News 0 d | $93.2 1.21% 1.1M |

Finance

| -11.6% | O: -0.32% H: 0.69% C: -0.27%
ESPR | $2.035 6.54% 2.3M |

Health Technology

| -84.04% | O: 0.25% H: 1.17% C: -3.25%
treatment cholesterol

---

Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M |

Health Technology

| 5.72% | O: 0.2% H: 0.59% C: -1.08%
disease treatment eye eye disease trial

---

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
CADL | $5.75 3.79% 170K |

| -32.02% | O: 1.84% H: 28.19% C: 20.0%
media treatment risk prostate cancer cancer phase 3 trial enroll

---

U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published: 2021-09-07 (Crawled : 13:15) - biospace.com/
GBT | $68.49 0.02% -0.02% |

Health Technology

| 127.13% | O: 1.23% H: 1.51% C: -2.39%
new drug disease treatment fda oxbryta children drug fda acceptance

---

Envista Announces Intended Sale Of KaVo Treatment Unit & Instrument Business To Planmeca
Published: 2021-09-07 (Crawled : 13:00) - prnewswire.com
NVST | $20.45 1.69% 380K |

Health Technology

| -54.26% | O: -1.23% H: 0.0% C: -1.01%
treatment

---

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Published: 2021-09-07 (Crawled : 12:15) - biospace.com/
RDY | $71.71 -0.61% 51K |

Health Technology

| 8.06% | O: 0.1% H: 0.0% C: -0.48%
CTXR | $0.7918 7.85% 220K |

Health Technology

| -64.9% | O: 3.37% H: 5.93% C: -1.4%
treatment immunotherapy therapy cancer license phase 3 t-cell e7777

---

MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
RARE F | $45.26 3.59% 330K |

Health Technology

| -56.54% | O: 1.8% H: 1.99% C: -0.35%
canada approval media treatment injection approval

---

Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
NTRA | News S | $92.165 4.01% 260K |

Health Services

| -26.88% | O: 1.99% H: 1.12% C: -0.91%
treatment test cancer

---

Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
MRK | $127.065 0.1% 2.2M |

Health Technology

| 64.32% | O: -0.85% H: 0.37% C: -0.8%
treatment china therapy keytruda

---

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors
Published: 2021-09-07 (Crawled : 10:00) - prnewswire.com
RNXT | $1.23 990 |

| -84.41% | O: 41.19% H: 0.09% C: -10.68%
treatment solid tumors liver clearance designation

---

Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
Published: 2021-09-07 (Crawled : 09:00) - biospace.com/
AUTL | $4.645 1.86% 310K |

Health Technology

| -36.31% | O: 1.96% H: 2.88% C: 0.68%
treatment acquisition opioid chronic pain

---

Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Published: 2021-09-07 (Crawled : 07:00) - globenewswire.com
TLSA | News | $0.761 0.98% 2.2M |

Health Technology

| -60.94% | O: 4.69% H: 1.99% C: -1.0%
treatment foralumab cancer antibody license car-t

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.595 164.08% 13M |

AGBA | $2.355 88.4% 34M |

Finance

CZOO | $9.32 86.77% 18M |

EDBL | News | $6.75 79.52% 1.5M |

MTC | $2.28 46.15% 2.6M |

Technology Services

OPRT | News | $3.14 39.56% 7.6M |

Finance

VNRX | $0.8 33.33% 2.9M |

Health Technology

MLEC | $1.865 33.21% 2.4M |

n/a

PALI | $6.37 29.21% 21M |

Manufacturing

LOCL | $3.33 27.59% 43K |

---

Your saved searches

---